High Dose Chemotherapy and Autologous Transplant for Breast Cancer

Graft vs Host Disease Clinical Trial

Official title:

High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00186641
• Other study ID #: BMT42
• Status: Active, not recruiting
• Phase: Phase 2
• First received: September 14, 2005
• Last updated: July 10, 2007
• Est. completion date: March 2005

Study information

• Verified date: July 2007
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 0
• Est. completion date: March 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Stage II, III or IV breast cancer

• chemosensitive

• adequate organ function

Exclusion Criteria:

• prior transplant,

• life threatening disease

• brain metastases

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Graft vs Host Disease

Intervention

Procedure:
• high dose chemo and auto hematopoietic cell transplant

Locations

Country	Name	City	State
United States	Stanford University Cancer Center	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival